Portage Biotech
22 FOLLOWERS
Despite advances in the immuno-oncology field, 70-80% of patients do not respond or have a limited response to existing therapies, such as checkpoint inhibitors. Portage Biotech aims to change this with a unique approach that drives the development of first-in-class immuno-oncology therapies for patients with cancer. Stay up to date with the latest news, discoveries, updates and more!
Portage Biotech
9M ago
The post business of biotech: Biotech Cash Management With Allan Shaw appeared first on Portage Biotech ..read more
Portage Biotech
9M ago
The post pharma’s Almanac: How is an increased focus on patient-centric concerns influencing the way that you work? appeared first on Portage Biotech ..read more
Portage Biotech
9M ago
The post PM360: The State of the Union in Cancer Innovation appeared first on Portage Biotech ..read more
Portage Biotech
9M ago
The post Life Science Leader: Ways To Face New Bio Funding & Banking Risks appeared first on Portage Biotech ..read more
Portage Biotech
9M ago
The post OncLive: Dr. Coupe on the Investigation of IMM60 Plus Pembrolizumab in Advanced Melanoma and NSCLC appeared first on Portage Biotech ..read more
Portage Biotech
9M ago
The post OncologyTube: IMM60 and Pembrolizumab Study for Advanced Melanoma & NSCLC appeared first on Portage Biotech ..read more
Portage Biotech
9M ago
The post Business of Biotech: The Innovation Reduction Act With Allan Shaw appeared first on Portage Biotech ..read more
Portage Biotech
9M ago
The post Molecule to Market: Meet the lean, keen biotech appeared first on Portage Biotech ..read more
Portage Biotech
9M ago
The post Molecule to Market: Why biotechs are feeling the bite appeared first on Portage Biotech ..read more
Portage Biotech
9M ago
The post GEN: Making the Transition from Academia to CEO appeared first on Portage Biotech ..read more